Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Reactogenicity of 2024-2025 COVID-19 Vaccines in HCW and First Responders
NCT06633835Phase 4Completed
- Sponsor
- Novavax
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started Sep 2024; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06633835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633835.